Proposal for Patient Obligations for Access to Unapproved Medical Interventions: Both Too Much and Not Enough

American Journal of Bioethics

Volumn 14, Issue 11, 2014, Pages 25-26

  Chapman, Audrey ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPASSIONATE USE; EVIDENCE BASED MEDICINE; HUMAN; INFORMATION PROCESSING; MORALITY; PATIENT; RESEARCH ETHICS;

COMPASSIONATE USE TRIALS; DATA COLLECTION; ETHICS, RESEARCH; EVIDENCE-BASED MEDICINE; HUMANS; MORAL OBLIGATIONS; PATIENTS;

EID: 84908030858     PISSN: 15265161     EISSN: 15360075     Source Type: Journal    
DOI: 10.1080/15265161.2014.957419     Document Type: Note

References (10)

1. Abigail Alliance for Better Access to Developmental Drugs v Von Eschenbach. 2006. 445 F3rd 470 (D.C. Cir.).
2. Bellamy, I. 2014. The illusions of “right to try” laws. Science-Based Medicine. March 6. Available at: http://www/sciencebasedmedicine.org/the-illusions-of-right-to-try-laws
3. Bender, S., L. Flicker, and R. Rhodes. 2007. Access for the terminally ill to experimental medical innovations: A three-pronged threat. American Journal of Bioethics 7(10): 3–6.
4. Caplan, A. 2007. Is it sound public policy to let the terminally ill access experimental medical innovations? American Journal of Bioethics 7(6): 1–3.
5. Food and Drug Administration. 2009. 21 CFR Parts 312 and 316, Final Rule, Federal Register 74(155): 40900–40945.
6. Leonard, E. W. 2009. Right to experimental treatment: FDA New approval, constitutional rights, and the public's health. Journal of Law, Medicine & Ethics 372(Summer): 2–12.
7. Okie, S. 2006. Access before approval—A right to take experimental drugs. New England Journal of Medicine 355(August 3): 437–440.
8. Ollove, M. 2014. Right-to-try for the terminally ill. USA Today. June 19. Available at: http://www.usatoday.com/story/news/nation/2014/06/19/stateline-fda
9. Walker, M. J., W. A. Rogers, and V. Entwistle. 2014. Ethical justifications for access to unapproved medical interventions: An argument for (limited) patient obligations. American Journal of Bioethics 14(11): XX–XX.
10. Wilenzick, M. 2007. Letter re Docket No 2006N-0061 dated February 14, Charging for investigational drugs. Available at: http://www.fda.gov/dockets/ecomments